Skip to content

A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM

A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01523405
Acronym
INSIGHT
Enrollment
4911
Registered
2012-02-01
Start date
2012-03-31
Completion date
2013-02-28
Last updated
2014-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes Mellitus

Keywords

Non Interventional Study, Type II Diabetes Mellitus, Quality of Life

Brief summary

This is a non-interventional, cross sectional, multicentric study in T2DM patients which will involve a single visit for study related procedures. This study will be conducted in approximately 5,000 patients at around 300 hospitals/primary care clinics across India. Approximately 18-20 patients per site will be enrolled. This study has been designed to evaluate diabetes related quality of life (DQoL), frequency and impact of hypoglycaemia in relation to HbA1c control and to assess disease modifying variables-BMI and BP in T2DM patients on oral / injectable anti-diabetic drugs with/without insulin therapy.

Detailed description

A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)

Interventions

None listed

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with diagnosis of T2DM for \> 1 year prior to entry in the study willing and able to complete the questionnaire and on pharmacotherapy * Patients who are currently treated with a single or combination of injectable/oral antidiabetic drugs with or without insulin therapy * Treatment type must be unchanged in the previous 3 months. However, dose modifications are allowed * Patients who agree to participate in the study and give their written informed consent

Exclusion criteria

* Patients with type 1 diabetes * Patients with diabetic ketoacidosis and/or hyperosmolar hyperglycaemic state * Patients with secondary diabetes (including disease of the exocrine pancreas, endocrinopathies) * Patients with concurrent treatment involving systemic glucocorticoids. However, inhaled, locally injected and topical use of glucocorticoids is allowed * Patients suffering from severe cardiac, hepatic, renal diseases as judged by the investigator * Any condition of the patient which may have an impact on objective and outcome of the trial example: patients currently undergoing major/ minor surgical

Design outcomes

Primary

MeasureTime frame
Diabetic Quality of Life using Modified 15 item DQoL (MDQoL) questionnaire2nd February 2012 - 2nd August 2012

Secondary

MeasureTime frame
HbA1c and its correlation with frequency of hypoglycemia2nd February 2012 - 2nd August 2012
Frequency and impact of hypoglycemia using HFS-II (worry subscale)2nd February 2012 - 2nd August 2012
Disease modifying variables Body Mass Index (BMI) and Blood Pressure (BP)2nd February 2012 - 2nd August 2012

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026